Table 1.
Summary of clinical and demographic characteristics of patients in Group 1 and Group 2
| Variables | All patients | Group 1 (BCVA ≤ 20/200) (N = 14) |
Group 2 (BCVA > 20/200) (N = 26) |
p-value | |||
|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | ||
| Age | 46.80 | 12.20 | 52.21 | 13.47 | 43.88 | 10.60 | *0.038 |
| Follow-up (months) | 30.70 | 28.39 | 28.27 | 27.99 | 35.21 | 29.61 | 0.747 |
| Refractive error(D) | −3.29 | 3.51 | −2.26 | 2.65 | −3.72 | 3.78 | 0.589 |
| Central retinal thickness (μm) | 267.18 | 52.18 | 256.86 | 39.40 | 272.73 | 57.86 | 0.366 |
| Subfoveal Choroidal thickness (μm) | 107.91 | 53.54 | 73.93 | 43.31 | 126.20 | 50.02 | *0.002 |
| N | % | N | % | N | % | ||
| Male | 15 | 37.50 | 4 | 28.60 | 11 | 42.30 | 0.502 |
| Crystalline deposits | 35 | 87.50 | 10 | 71.40 | 25 | 96.20 | *0.043 |
| EZ disruption at fovea | 18 | 45.00 | 13 | 92.90 | 5 | 19.20 | * < 0.001 |
| Outer retinal tubulation | 20 | 50.00 | 5 | 35.70 | 15 | 57.70 | 0.185 |
| Sclerotic vessels | 35 | 87.50 | 13 | 92.90 | 22 | 84.60 | 0.640 |
| FAF staging | 0.122 | ||||||
| Stage 1 | 5 | 12.50 | 1 | 7.10 | 4 | 15.40 | 0.64 |
| Stage 2 | 17 | 42.50 | 5 | 35.70 | 12 | 46.20 | 0.524 |
| Stage 3 | 11 | 27.50 | 7 | 50.00 | 4 | 15.40 | *0.029 |
BCVA best corrected visual acuity, SD standard deviation, N number, EZ ellipsoid zone, FAF fundus autofluorescence
*p < 0.05